Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

Neuropathic pain is a severe clinical condition caused by damage to the nervous system. It often feels like a burning, ...

Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and ...

The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) stock is trading higher on Monday after the company released new preclinical ...

has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and tolerability of QUTENZA ® (capsaicin) 8% topical system in post-surgical neuropathic ...

Dogwood's expanded pipeline includes three late-stage assets: Halneuron ®, currently in Phase 2b development for chemotherapy ...

European researchers have mapped the most comprehensive phenotyping of neuropathic pain and identified genetic markers associated with this serious condition.

The Company’s novel pipeline is based on Nobel Prize winning research and includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for ...

With a history of spinal injury and having not undergone a surgical stabilization, a syrinx was suspected. A magnetic resonance imaging (MRI) study of the patient's cervical and thoracic spine was ...

Neuropathic pain is a chronic and debilitating condition that impacts around 10% of the population in both the United States and Europe. Despite advances in understanding the mechanisms of neuropathic ...

European researchers have mapped the most comprehensive phenotyping of neuropathic pain and identified genetic markers associated with this serious condition. Long-term, low-dose antiviral ...